Mutation load has been shown in retrospective analysis to be a predictive biomarker for clinical benefit from single-agent anti-PD-1/PD-L1 agents in certain tumor types such as melanoma, NSCLC, bladder, and HNSCC [9, 49–51]. This evidence concerns the gene PDCD1 and melanoma.